论文部分内容阅读
1980～1990年,我们摸索了尿激酶静脉治疗急性心肌梗塞的剂量。第一期:小剂量组36人,胸痛缓解治疗组比对照组为75.0％对16.7％,抬高的ST段比原来下降50.0％对8.0％,FDP升高94.4％。第二期:试用大剂量组12人,此期再分为两个亚组:较大剂量组7人(>80万U),较小剂量组5人(<30万U)。较大剂量组3人符合明确再通标准(42.9％),但2人发生心脏破裂,可能与再灌注损伤有关;较小剂量组无人达再通指标。第三期;综合剂量组52人,都有对照组,根据不同发病时闻给予大中小三种剂量,死亡率最低,疗效显著。对UK的除溶栓和改善血液粘稠度作用进行了讨论。
From 1980 to 1990, we explored the dose of intravenous urokinase for acute myocardial infarction. The first phase: 36 patients in low-dose group, chest pain relief treatment group than the control group was 75.0% to 16.7%, elevated ST segment decreased from 50.0% to 8.0%, FDP increased 94.4%. Phase II: Trial high-dose group of 12 people, this period is divided into two sub-groups: the larger dose group of 7 (> 800000 U), the smaller dose group of 5 (<300000 U). In the larger dose group, 3 patients met the criteria of recanalization (42.9%), but 2 patients had heart rupture, which may be related to reperfusion injury. The third phase; comprehensive dose group of 52 people, have a control group, according to different incidence of large, medium and small doses of the three doses, the lowest mortality, significant effect. The role of the UK in thrombolysis and improving blood viscosity was discussed.